Brind.

Charles Lynde authorized a CTA for Thykamine clinical trials in Markham, involving Health Canada and Devonian Health Group Inc.

1 report, 1 independent Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Charles Lynde authorized a CTA for Thykamine clinical trials in Markham, involving Health Canada and Devonian Health Group Inc.

Who's involved

What this event is mainly about
Charles LyndeHealth Canada

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped